Dik J Kwekkeboom

Summary

Affiliation: Erasmus MC
Country: The Netherlands

Publications

  1. ncbi Somatostatin receptor imaging
    Dik J Kwekkeboom
    Department of Nuclear Medicine, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands
    Semin Nucl Med 32:84-91. 2002
  2. ncbi Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors
    Dik J Kwekkeboom
    Department of Nuclear Medicine, Erasmus Medical Center, Dr Molewaterplein 40, 3015 GD Rotterdam, Netherlands
    J Clin Oncol 23:2754-62. 2005
  3. ncbi Treatment of patients who have endocrine gastroenteropancreatic tumors with radiolabeled somatostatin analogues
    Dik J Kwekkeboom
    Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    Hematol Oncol Clin North Am 21:561-73; x. 2007
  4. ncbi Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma
    Martijn van Essen
    Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    J Nucl Med 47:1599-606. 2006
  5. ncbi Well-differentiated duodenal tumor/carcinoma (excluding gastrinomas)
    Robert T Jensen
    Digestive Diseases Branch, NIDDK, NIH, Bethesda, MD, USA
    Neuroendocrinology 84:165-72. 2006
  6. ncbi Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival
    Dik J Kwekkeboom
    Department of Nuclear Medicine, Erasmus Medical Center, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    J Clin Oncol 26:2124-30. 2008
  7. ncbi Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors
    Dik J Kwekkeboom
    Department of Nuclear Medicine, Erasmus Medical Center, s Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
    Endocrinol Metab Clin North Am 40:173-85, ix. 2011
  8. ncbi ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs
    Dik J Kwekkeboom
    Department of Nuclear Medicine, Erasmus University Medical Center, NL 3015 Rotterdam, The Netherlands
    Neuroendocrinology 90:220-6. 2009
  9. ncbi Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors
    Dik J Kwekkeboom
    Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    Semin Nucl Med 40:78-88. 2010
  10. ncbi Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs
    Dik J Kwekkeboom
    Department of Nuclear Medicine, Erasmus Medical Center, University Hospital Rotterdam, Rotterdam, The Netherlands
    J Nucl Med 46:62S-6S. 2005

Detail Information

Publications50

  1. ncbi Somatostatin receptor imaging
    Dik J Kwekkeboom
    Department of Nuclear Medicine, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands
    Semin Nucl Med 32:84-91. 2002
    ..The development of Peptide Receptor Radionuclide Therapy (PRRT) is expected to stimulate peptide receptor imaging...
  2. ncbi Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors
    Dik J Kwekkeboom
    Department of Nuclear Medicine, Erasmus Medical Center, Dr Molewaterplein 40, 3015 GD Rotterdam, Netherlands
    J Clin Oncol 23:2754-62. 2005
    ..Chemotherapy can be effective, but the response is usually less than 1 year. Here, we present the results of treatment with a radiolabeled somatostatin analog, [177Lu-DOTA0,Tyr3]octreotate (177Lu-octreotate)...
  3. ncbi Treatment of patients who have endocrine gastroenteropancreatic tumors with radiolabeled somatostatin analogues
    Dik J Kwekkeboom
    Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    Hematol Oncol Clin North Am 21:561-73; x. 2007
    ..Also, if kidney-protective agents are used, the side effects of this therapy are few and mild. These data compare favorably with the limited number of alternative treatment approaches...
  4. ncbi Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma
    Martijn van Essen
    Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    J Nucl Med 47:1599-606. 2006
    ..Here we present the effects of this therapy in a small number of patients with metastasized or inoperable paragangliomas, meningiomas, small cell lung carcinomas (SCLCs), and melanomas...
  5. ncbi Well-differentiated duodenal tumor/carcinoma (excluding gastrinomas)
    Robert T Jensen
    Digestive Diseases Branch, NIDDK, NIH, Bethesda, MD, USA
    Neuroendocrinology 84:165-72. 2006
  6. ncbi Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival
    Dik J Kwekkeboom
    Department of Nuclear Medicine, Erasmus Medical Center, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    J Clin Oncol 26:2124-30. 2008
    ..Here we report on the toxicity and efficacy of this treatment, performed in over 500 patients...
  7. ncbi Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors
    Dik J Kwekkeboom
    Department of Nuclear Medicine, Erasmus Medical Center, s Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
    Endocrinol Metab Clin North Am 40:173-85, ix. 2011
    ..Overall survival is several years from diagnosis. These data compare favorably with the limited number of alternative treatments. If more widespread use of PRRT can be guaranteed, such therapy may become the therapy of first choice...
  8. ncbi ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs
    Dik J Kwekkeboom
    Department of Nuclear Medicine, Erasmus University Medical Center, NL 3015 Rotterdam, The Netherlands
    Neuroendocrinology 90:220-6. 2009
    ....
  9. ncbi Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors
    Dik J Kwekkeboom
    Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    Semin Nucl Med 40:78-88. 2010
    ..If more widespread use of peptide receptor radionuclide therapy can be guaranteed, such therapy may well become the therapy of first choice in patients with metastasized or inoperable gastroenteropancreatic neuroendocrine tumors...
  10. ncbi Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs
    Dik J Kwekkeboom
    Department of Nuclear Medicine, Erasmus Medical Center, University Hospital Rotterdam, Rotterdam, The Netherlands
    J Nucl Med 46:62S-6S. 2005
    ..These data compare favorably with those for the limited number of alternative treatment approaches...
  11. ncbi Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors
    Dik J Kwekkeboom
    Department of Nuclear Medicine, Erasmus Medical Center, s Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
    Endocr Relat Cancer 17:R53-73. 2010
    ..If more widespread use of PRRT can be guaranteed, such therapy may well become the therapy of first choice in patients with metastasized or inoperable GEPNETs...
  12. ncbi Endocrine tumours of the gastrointestinal tract. Peptide receptor radionuclide therapy
    Jaap J M Teunissen
    Department of Nuclear Medicine, Erasmus MC, Rotterdam GD, The Netherlands
    Best Pract Res Clin Gastroenterol 19:595-616. 2005
    ....
  13. ncbi Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings
    Marion de Jong
    Department of Nuclear Medicine, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands
    Semin Nucl Med 32:133-40. 2002
    ..These data show that radionuclide therapy with radiolabelled somatostatin analogs, like [DOTA, Tyr(3)]octreotide and [DOTA, Tyr(3)octreotate is a most promising new treatment modality for patients who have sst(2)-positive tumors...
  14. ncbi Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours
    Martijn van Essen
    Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 35:743-8. 2008
    ..Adding capecitabine to (177)Lu-octreotate, as a radio-sensitiser, may enhance these anti-tumour effects. We now present the short-term toxicity profile of this novel combination...
  15. ncbi Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0),Tyr(3)]octreotate
    Flavio Forrer
    Department of Nuclear Medicine, Erasmus MC Rotterdam, Dr Molewaterplein 40, NL 3015 GD, Rotterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 36:1138-46. 2009
    ..Also, we evaluated the absorbed cross-dose from the source organs (liver, spleen, kidneys and blood), tumours and the so-called "remainder of the body" to the bone marrow...
  16. ncbi Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0,Tyr3]octreotate
    Saima Khan
    Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    J Nucl Med 52:1361-8. 2011
    ..In this study, we investigated the QOL and symptoms after [(177)Lu-DOTA(0),Tyr(3)]octreotate ((177)Lu-octreotate) therapy in patients with inoperable or metastasized gastroenteropancreatic or bronchial neuroendocrine tumors (NETs)...
  17. ncbi Somatostatin receptor imaging for neuroendocrine tumors
    Wouter W de Herder
    Department of Internal Medicine, Section of Endocrinology, Erasmus MC, Rotterdam, The Netherlands
    Pituitary 9:243-8. 2006
    ..However, a large variety of lesions in and around the pituitary region also express somatostatin receptors and, therefore, can be visualized by (111)In-pentetreotide scintigraphy...
  18. ncbi Diagnostic imaging of dopamine receptors in pituitary adenomas
    Wouter W de Herder
    Departments of Internal Medicine and Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
    Eur J Endocrinol 156:S53-6. 2007
    ..Dopamine D2 receptors on pituitary tumours can also be studied using positron emission tomography with (11)C-N-raclopride and (11)C-N-methylspiperone...
  19. ncbi Molecular imaging as in vivo molecular pathology for gastroenteropancreatic neuroendocrine tumors: implications for follow-up after therapy
    Eric P Krenning
    Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    J Nucl Med 46:76S-82S. 2005
    ....
  20. ncbi Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors
    Roelf Valkema
    Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
    Semin Nucl Med 36:147-56. 2006
    ..Although the objective response after therapy with [(90)Y-DOTA(0),Tyr(3)]-octreotide by standard criteria seems modest, the significantly longer OS compared with historic controls is most encouraging...
  21. ncbi Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate
    Bart de Keizer
    Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 35:749-55. 2008
    ..The aim of this study was to investigate the incidence of hormonal crises after therapy with the radiolabeled somatostatin analogue [(177)Lu-DOTA(0),Tyr(3)]octreotate ((177)Lu-octreotate)...
  22. ncbi Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin
    Martijn van Essen
    Department of Nuclear Medicine, Erasmus MC, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 34:1219-27. 2007
    ..As patients with foregut carcinoids may respond differently, we here present the effects of this treatment in a subgroup of patients with foregut carcinoids of bronchial, gastric or thymic origin...
  23. ncbi Tumor imaging and therapy using radiolabeled somatostatin analogues
    Marion de Jong
    Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
    Acc Chem Res 42:873-80. 2009
    ..We expect improvements in the development of new peptide analogues: such advances could reduce side effects and allow for the use of combination therapy (for example, combining radiopeptide analogues with chemotherapeutics)...
  24. ncbi (68)Ga-labeled DOTA-peptides and (68)Ga-labeled radiopharmaceuticals for positron emission tomography: current status of research, clinical applications, and future perspectives
    Wouter A P Breeman
    Department of Nuclear Medicine, Erasmus MC Rotterdam, The Netherlands
    Semin Nucl Med 41:314-21. 2011
    ..As soon as these are achieved, a whole new radiopharmacy providing PET radiopharmaceuticals might develop...
  25. ncbi Effects of therapy with [177Lu-DOTA 0,Tyr 3]octreotate on endocrine function
    Jaap J M Teunissen
    Department of Nuclear Medicine, Erasmus Medical Center, 3015 CE Rotterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 36:1758-66. 2009
    ..We determined the effects of PRRT with [(177)Lu-DOTA(0),Tyr(3)]octreotate ((177)Lu-octreotate) on glucose homeostasis and the pituitary-gonadal, pituitary-thyroid and pituitary-adrenal axes...
  26. ncbi Neuroendocrine tumors. Peptide receptor radionuclide therapy
    Flavio Forrer
    Department of Nuclear Medicine, Erasmus Medical Centre Rotterdam, Dr Molewaterplein 40, NL 3015 GD Rotterdam, The Netherlands
    Best Pract Res Clin Endocrinol Metab 21:111-29. 2007
    ..Furthermore, clinical issues--including indication and timing of therapy--are discussed. Finally, important directions for future research are mentioned to illustrate new strategies for increasing therapy efficacy...
  27. ncbi Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours
    Martijn van Essen
    Department of Nuclear Medicine, Erasmus MC, s Gravendijkwal 230, Rotterdam, CE, The Netherlands
    Acta Oncol 46:723-34. 2007
    ..Also the role in somatostatin receptor expressing non-GEP tumours, like metastasised paraganglioma/pheochromocytoma and non-radioiodine-avid differentiated thyroid carcinoma might become more important...
  28. ncbi Preclinical and clinical studies of peptide receptor radionuclide therapy
    Stefan E Pool
    Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
    Semin Nucl Med 40:209-18. 2010
    ..This review summarizes results of PRRT and describes clinical and preclinical studies regarding PRRT optimizing strategies...
  29. ncbi Peptide-receptor radionuclide therapy for endocrine tumors
    Martijn van Essen
    Department of Nuclear Medicine, Erasmus Medical Centre, Rotterdam, The Netherlands
    Nat Rev Endocrinol 5:382-93. 2009
    ..If these results can be replicated in large, controlled trials, PRRT might become the preferred option in patients with metastatic or inoperable gastroenteropancreatic neuroendocrine tumors...
  30. ncbi Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate
    Roelf Valkema
    Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    J Nucl Med 46:83S-91S. 2005
    ....
  31. ncbi Salvage therapy with (177)Lu-octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumors
    Martijn van Essen
    Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
    J Nucl Med 51:383-90. 2010
    ..We present the effects of additional therapy with (177)Lu-octreotate in patients in whom progressive disease developed after an initial benefit from regular therapy...
  32. ncbi Tumor response assessment to treatment with [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors: differential response of bone versus soft-tissue lesions
    Esther I van Vliet
    Department of Nuclear Medicine, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    J Nucl Med 53:1359-66. 2012
    ..We therefore compared the response of bone lesions with that of soft-tissue lesions to treatment with (177)Lu-octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors (NETs)...
  33. ncbi Peptide receptor radionuclide therapy for non-radioiodine-avid differentiated thyroid carcinoma
    Jaap J M Teunissen
    Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    J Nucl Med 46:107S-14S. 2005
    ..The uptake of radioactivity in tumors was also studied in relation to treatment outcome...
  34. ncbi Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3]octreotate
    Jaap J M Teunissen
    Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    J Clin Oncol 22:2724-9. 2004
    ..To evaluate the quality of life (QoL) in patients with metastatic somatostatin receptor positive gastroenteropancreatic tumors treated with [(177)Lu-DOTA(0),Tyr(3)]octreotate ((177)Lu-octreotate) therapy...
  35. ncbi Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours
    Jaap J M Teunissen
    Department of Nuclear Medicine, Erasmus Medical Centre, Rotterdam, The Netherlands
    Endocr Relat Cancer 18:S27-51. 2011
    ..In the largest group of patients receiving PRRT, treated with [(177)Lu-DOTA(0),Tyr(3)]octreotate, a survival benefit of several years compared with historical controls has been reported...
  36. ncbi Dopamine agonist therapy of clinically non-functioning pituitary macroadenomas. Is there a role for 123I-epidepride dopamine D2 receptor imaging?
    Wouter W de Herder
    Department of Internal Medicine, Section of Endocrinology, Erasmus MC, s Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
    Eur J Endocrinol 155:717-23. 2006
    ..We have studied the correlation between in vivo imaging of D2 receptors using (123)I-epidepride and the radiological response of NFPA to DA in 18 patients...
  37. ncbi Staging and treatment of differentiated thyroid carcinoma with radiolabeled somatostatin analogs
    Jaap J M Teunissen
    Department of Nuclear Medicine, Erasmus Medical Center, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    Trends Endocrinol Metab 17:19-25. 2006
    ..Promising, novel, radiolabeled somatostatin analogs that have a broader receptor affinity profile and, thus, a potentially wider therapeutic range are being tested clinically...
  38. ncbi Peptide receptor radionuclide therapy
    Eric P Krenning
    Department of Nuclear Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands
    Ann N Y Acad Sci 1014:234-45. 2004
    ..Multireceptor tumor targeting using the combination of bombesin and NPY(Y(1)) analogues is promising for scintigraphy and PRRT of breast carcinomas and their lymph node metastases...
  39. ncbi Octreoscan radioreceptor imaging
    Aart J van der Lely
    Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
    Endocrine 20:307-11. 2003
    ..The value of somatostatin receptor imaging in patients with other tumors, like breast cancer, or in patients with granulomatous diseases, has to be established...
  40. ncbi Preclinical comparison of (111)In-labeled DTPA- or DOTA-bombesin analogs for receptor-targeted scintigraphy and radionuclide therapy
    Wouter A P Breeman
    Department of Nuclear Medicine, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands
    J Nucl Med 43:1650-6. 2002
    ..Radiometal-labeled diethylenetriaminepentaacetic acid (DTPA)-BN derivatives are potentially useful radioligands for receptor-targeted scintigraphy and radiotherapy of GRP receptor-expressing tumors...
  41. ncbi Well-differentiated pancreatic tumor/carcinoma: insulinoma
    Wouter W de Herder
    Department of Internal Medicine, Section of Endocrinology, Erasmus MC, Rotterdam, The Netherlands
    Neuroendocrinology 84:183-8. 2006
  42. ncbi Increased mammary uptake on 111In pentetreotide scintigraphy
    Stoffel F J Van Eeckhoudt
    Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    Clin Nucl Med 37:781-2. 2012
    ..Estradiol levels during the menstrual cycle could therefore explain the variable degree of uptake commonly seen in premenopausal women...
  43. ncbi Diffuse lung and stomach uptake of Tc-99m oxidronate (HDP)
    Jan-Paul Esser
    Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
    Clin Nucl Med 28:845-6. 2003
  44. ncbi In vivo and in vitro detection of dopamine d2 receptors in uveal melanomas
    Lisa Bodei
    Department of Nuclear Medicine, Erasmus University Medical Centre, Rotterdam, The Netherlands
    Cancer Biother Radiopharm 18:895-902. 2003
    ..Although further studies on larger series are needed, 123I-epidepride could represent a future tool to study the expression of D2R in other classes of neuroendocrine tumors...
  45. ncbi Neoadjuvant downsizing by internal radiation: a case for preoperative Peptide receptor radionuclide therapy in patients with pancreatic neuroendocrine tumors
    Samer Ezziddin
    From the Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany Department of Surgery, Malteser Hospital Duisburg, Duisburg, Germany Oncology Center Duisburg, Duisburg, Germany Department of Radiology, University Hospital Bonn, Bonn, Germany and Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, Netherlands
    Clin Nucl Med 37:102-4. 2012
    ..The patient has been in complete local remission for 22 months. This case demonstrates the potential of preoperative PRRT to improve resectability of initially inoperable pancreatic endocrine tumors...
  46. ncbi Multimodality management of a polyfunctional pancreatic endocrine carcinoma with markedly elevated serum vasoactive intestinal polypeptide and calcitonin levels
    Aejaz Nasir
    Department of Interdisciplinary Oncology, Neuroendocrine Cancer Research Group, H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL 33612, USA
    Pancreas 36:309-13. 2008
    ..In summary, this is a unique case of metastatic VIP- and calcitonin-secreting pancreatic ECA with dramatic sustained clinical, biochemical, and objective tumor response to peptide receptor radionuclide therapy...
  47. ncbi Poorly differentiated carcinomas of the foregut (gastric, duodenal and pancreatic)
    Ola Nilsson
    Department of Pathology, Gothenburg University, Gothenburg, Sweden
    Neuroendocrinology 84:212-5. 2006
  48. ncbi Well-differentiated gastric tumors/carcinomas
    Philippe Ruszniewski
    Department of Gastroenterology, Beaujon Hospital, Clichy, France
    Neuroendocrinology 84:158-64. 2006
  49. ncbi Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary
    Thomas Steinmuller
    DRK Kliniken Westend, Berlin, Germany
    Neuroendocrinology 87:47-62. 2008
  50. ncbi Well-differentiated pancreatic nonfunctioning tumors/carcinoma
    Massimo Falconi
    Department of Surgery, University of Verona, Verona, Italy
    Neuroendocrinology 84:196-211. 2006